Candriam S.C.A. Kinnate Biopharma Inc. Transaction History

Candriam S.C.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $362,629 - $840,390	68,941 Added 103.89%	135,298 $825,000
Q3 2022 Nov 10, 2022	BUY	$9.86 - $15.76 $654,280 - $1.05 Million	66,357 New	66,357 $793,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.